CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenues:
Net product sales	$ 362,378	$ 318,740
Sanofi collaboration revenue	130,508	99,273
Bayer HealthCare collaboration revenue	125,312	14,907
Technology licensing and other revenue	7,542	6,744
Total revenues	625,740	439,664
Expenses:
Research and development	287,379	180,299
Selling, general, and administrative	108,850	77,260
Cost of goods sold	27,473	28,021
Cost of collaboration manufacturing	16,099	1,034
Total expenses	439,801	286,614
Income from operations	185,939	153,050
Other income (expense):
Investment income	937	456
Interest expense	(11,613)	(11,675)
Total other income (expense)	(10,676)	(11,219)
Income before income taxes	175,263	141,831
Income tax expense	(109,820)	(42,957)
Net income	65,443	98,874
Net income per share - basic	$ 0.66	$ 1.02
Net income per share - diluted	$ 0.58	$ 0.90
Weighted average shares outstanding - basic	98,709	96,878
Weighted average shares outstanding - diluted	112,151	109,369
Statements of Comprehensive Income
Net income	65,443	98,874
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	2,653	(478)
Comprehensive income	$ 68,096	$ 98,396